• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Blogs » The Carlat Psychiatry Podcast » Ketamine Assisted Therapy Part I

The Carlat Psychiatry Podcast
The Carlat Psychiatry Podcast RSS FeedRSS

Clear, engaging, and practical updates on clinical psychiatry.
Earn CME for listening to the podcast with a Podcast CME Subscription.
Listen for free here or using Apple Podcasts and Spotify.
General Psychiatry

Ketamine Assisted Therapy Part I

June 24, 2024
Chris Aiken, MD, Kellie Newsome, PMHNP, and Kyle T. Greenway, MD, MSc

Chris Aiken, MD, Kellie Newsome, PMHNP, and Kyle Greenway, MD, have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

shutterstock_2479647635.jpg
Indoor photo of normally dressed person with an iv laying down in a chair with an eyemask on | Shutterstock


Kyle Greenway developed the Montreal Model to pair ketamine with psychotherapy. In this 3-part series, he shows us how to do it. 


Publication Date: 06/24/2024

Duration: 19 minutes, 13 seconds


Transcript:

CHRIS AIKEN: We get into the nitty gritty of ketamine assisted therapy with Kyle Greenway.

KELLIE NEWSOME: Welcome to the Carlat Psychiatry Podcast, keeping psychiatry honest since 2003.

CHRIS AIKEN: I’m Chris Aiken, the editor in chief of the Carlat Report. 

KELLIE NEWSOME: And I’m Kellie Newsome, a psychiatric NP and a dedicated reader of every issue.

CHRIS AIKEN: The last 2 episodes of this podcast might have left a bad taste in your mouth about psychedelic assisted therapy. If that’s the case, we have some mouthwash. In our June-July issue we featured an interview with Kyle Greenway, who runs a ketamine assisted therapy center at McGill University. And I promise this episode will be a lot more boring than our forway into MDMA therapy, in a good way. There’s no therapeutic touch, no spirit animals, and no shadow selves in this work. Dr. Greenway takes a straight forward approach that addresses some of the common problems we encounter when our patients go to get ketamine:


1. There is no end in sight. Ketamine works quickly, but it doesn’t last, which means many patients end up on chronic maintenance ketamine therapy. The longer they take it, the less it seems to work, and the harder it is to stop. Dr. Greenway prepares patients with an end date in sight. 

2. Therapy is not optional. In Dr. Greenway’s practice, ketamine is there to reduce their symptoms so they can start active therapy, which is where the lasting changes occur. He does not start ketamine until the patient is fully on board with this, which means they’ve formed a therapeutic alliance and they are starting to make behavior change. Like a dangling carrot, ketamine is started after the patient begins their behavioral change. Finally...

3. Benzos are cut. Around 50% of patients with treatment resistant depression take a benzodiazepine. We know that chronic benzo use is not therapeutic – yes, acute use might reduce depression – but chronic use is associated with possible greater depression. So what is the sense of adding another class of controlled substance on top of that?

Besides the unsightly polypharmacy, there are also empiric reasons to stop benzos before ketamine therapy. Ketamine works through glutamate and GABA agonists like benzos – and for that matter z-hypnotics – interact with glutamate in complex ways that may blunt ketamine’s effects. That is the theory, and several studies have found that ketamine is less effective for depression when benzos are on board, particularly if they are in high doses (Andrashko V et al, Front Psychiatry 2020;11:844).

So Dr. Greenway tells patients that they’ll need to taper their benzodiazepine before starting ketamine, and he’s found that ketamine is an excellent replacement for benzos, treating the withdrawal, effectively washing out withdrawal symptoms. In an open label case series he published, there was no worsening of depression, anxiety, or even sleep with this approach.

Dr. Greenway’s approach is called the Montreal Model. Unlike some psychedelic therapies, he isn’t trying to liberate consciousness, save the environment or bring about work peace. As a starting place, he just wants his patients to get out of bed. He begins with that basic behavioral approach – behavioral activation – and blends it into a more acceptance and commitment mindfulness approach in the therapy. We are going to go into an interview now where he describes all of the nitty gritty of what he does, but I will warn you, you may get more out of this interview if you read the online interview first, that's where he goes through the basics. This is where he goes into the more advanced stuff of what he actually does in the ketamine therapy sessions. Just a note that throughout this intwefiw we are talking about ketamine and the FDA approved esketamine SPRAVATO®, basically interchangeably, and that you can use these techniques with both treatments. However, there is some thinking that ketamine may be more likely to provoke a psychedelic – mind altering – kind of repose because it peaks at higher dose in the brain than esketamine.

....

KELLIE NEWSOME: Kyle Greenway is an Assistant Professor of Psychiatry at McGill University and Director of the ketamine-assisted therapy program at Jewish General Hospital in Montreal, Canada. Find his full review in our online addition for June 2024. 

CHRIS AIKEN: Join us next week for part II of this podcast.

KELLIE NEWSOME: The Carlat Podcast team is now on video. Find monthly episodes of Carlat Psychiatry News on the Carlat YouTube channel or under webinars on the Carlat webpage.




The Carlat CME Institute is accredited by the ACCME to provide continuing medical education for physicians. Carlat CME Institute maintains responsibility for this program and its content. Carlat CME Institute designates this enduring material educational activity for a maximum of one quarter (.25) AMA PRA Category 1 CreditsTM. Physicians or psychologists should claim credit commensurate only with the extent of their participation in the activity.




Related Products

Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • MFB7e_Print_App_Access.png

    Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

    The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2622607431.jpg
    General Psychiatry

    Should You Test MTHFR?

    MTHFR is a...
    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.